Corealis Pharma
Corealis Pharma is a Canadian CDMO specializing exclusively in oral solid dosage formulation development and Phase I/II GMP clinical manufacturing for emerging biotech, virtual biotech, and pharmaceutical companies, with integrated pre-formulation, analytical, HPAPI handling, and global clinical supply services.
- Company typePrivate
- Founded2005
- HeadquartersLaval, Canada
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Corealis Pharma does
Corealis Pharma Inc. is a privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Laval, Quebec, founded in 2005. The company specializes exclusively in oral solid dosage (OSD) form drug development and Phase I/II GMP clinical manufacturing, operating across two sites totaling more than 60,000 square feet of integrated formulation, analytical, HPAPI-handling (down to approximately 1 µg/m³ exposure), spray drying (500 g/day and 5 kg/batch), and packaging infrastructure. Its service offering is structured as five interconnected modules: pre-formulation/API characterization, formulation development, analytical services, GMP manufacturing, and packaging/labeling with global clinical supply distribution, typically delivering clinical supply within 4–6 months from project kickoff.
Corealis generates revenue through project-based B2B contracts with emerging biotech, mid-sized pharma, and virtual/asset-light biotech clients, supported by a direct sales motion led by a VP of Business Development and active participation in industry conferences (BIO, DDF Summit, AAPS PharmSci 360, BIO-Europe, ChemOutsourcing). Channel reach is augmented by marketplace listings on Science Exchange, Scientist.com, and Prendio-BioProcure. To extend beyond its Phase I/II scope, Corealis has built flagship strategic alliances with Bora Pharmaceuticals (announced December 2025, end-to-end commercial-scale pathway) and Rottendorf Pharma (announced February 2026, transatlantic European commercial supply pathway), positioning the integrated offering from pre-formulation through commercial launch.
The company is institutionally backed by ArchiMed (lead, through its MED III fund) and CDPQ since a 2022 private equity investment, with co-founders Yves Mouget and Patrick Gosselin remaining in VP roles alongside a new CEO, David Leroux-Petersen, and a CFO recruited from Sanofi (Pascal Tougas). Operational metrics cited include 900+ completed studies, 27 commercialized drug products representing over $10 billion in market value, more than 700 clinical trials supported across 28 countries, and a 100% on-time delivery record between 2020 and 2025. Capacity was doubled in 2024 and the company celebrated its 20th anniversary in 2025.
Corealis Pharma firmographics
Firmographics- Name
- Corealis Pharma
- Legal name
- Corealis Pharma Inc.
- Website
- https://corealispharma.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Corealis Pharma is a Canadian CDMO specializing exclusively in oral solid dosage formulation development and Phase I/II GMP clinical manufacturing for emerging biotech, virtual biotech, and pharmaceutical companies, with integrated pre-formulation, analytical, HPAPI handling, and global clinical supply services.
- Ownership category
- akta.pro rank
Corealis Pharma industry classification
Industry- Product category
- Pharmaceutical CDMO Services (Oral Solid Dosage)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ)
Keywords
Where Corealis Pharma is headquartered
LocationHeadquarters
- HQ city
- Laval
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Corealis Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- CDMO Contract Services: Corealis Pharma operates as a Contract Development and Manufacturing Organization (CDMO) providing specialized pharmaceutical development and manufacturing services. Revenue is generated through project-based contracts for formulation development, analytical services, GMP manufacturing, and clinical supply packaging. Services are priced per project with quotes provided based on scope and complexity.
- Clinical Supply Manufacturing: Phase-appropriate manufacturing of tablets and capsules for clinical trials, including packaging and labeling services for global clinical trial material distribution.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based pricing for CDMO services |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Corealis Pharma product offering
Product offeringCore offering
Corealis Pharma is a Contract Development and Manufacturing Organization (CDMO) that provides formulation development and clinical supplies manufacturing of solid oral dosage forms for biotech and pharmaceutical companies. Its services span OSD pre-formulation (API characterization), formulation development, analytical services, Phase I/II GMP manufacturing of tablets and capsules, and clinical packaging/labeling with global distribution. Typical timelines run 4–6 months from project kickoff to clinical trial supply.
Product overview
Corealis Pharma is a CDMO (Contract Development and Manufacturing Organization) providing integrated oral solid dosage (OSD) development and GMP clinical manufacturing services. The company offers five interconnected service modules: OSD Pre-Formulation (API characterization and compatibility studies), OSD Formulation Development (scalable formulation design), Analytical Services (method development, stability testing, GMP release), GMP Manufacturing (clinical batch production for Phase I/II), and Packaging & Labeling (clinical supply packaging and global distribution). Services are designed to guide molecules from early development through to clinical trial material delivery, with typical timelines of 4-6 months from kickoff to clinical supply.
Differentiator
Problem solved
Functional benefit
Products and services
- OSD Pre-Formulation API physicochemical characterization services including particle morphology (SEM), particle size distribution (laser diffraction), crystal state analysis (XRPD), thermal analysis (DSC/TGA), hygroscopicity testing (DVS), powder rheology and density testing, and compatibility studies. Designed for biotech and pharma clients preparing an oral solid dose candidate for formulation development.
- OSD Formulation Development Design and optimization of scalable oral solid dosage formulations (immediate, delayed, and sustained release tablets and capsules) tailored to API physicochemical properties and clinical program goals. Built for biotech and pharmaceutical clients advancing complex or poorly soluble molecules into the clinic.
- Analytical Services Comprehensive analytical development and testing including method development, impurity profiling, dissolution testing, stability programs, GMP release testing, and regulatory compliance support. Provided to biotech and pharmaceutical clients requiring analytical evidence underpinning formulation and manufacturing decisions.
- GMP Manufacturing Phase-appropriate manufacturing of tablets and capsules for Phase I and II clinical trials using processes including direct compression, wet and dry granulation, melt granulation, extrusion and spheronization, encapsulation, coating, solid dispersion, and spray drying (500 g/day to 5 kg/batch). Delivered to biotech and pharmaceutical clients with high-potency API handling capability (~1 µg/m3 exposure).
- Packaging & Labeling Clinical packaging and labeling services including blister packaging, bottling, pouching, blinded study packaging, patient kit preparation, and global clinical trial material distribution. Provided to biotech and pharmaceutical clients running Phase I/II trials worldwide.
Quantifiable outcome
- 4-6 months typical timeline from project kickoff to clinical trial supply
- +4 more outcomes
Companies that use Corealis Pharma
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Corealis Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature5 records
Corealis Pharma partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core, flagship and minor.
- Rottendorf PharmacoreStrategic transatlantic alliance for integrated early-to-late-stage OSD development from pre-formulation through commercial supply. Corealis leads R&D and Phase I-II clinical supply while Rottendorf manages Phase III, validation, and commercial manufacturing. Operates under joint execution and governance framework aligning formulation strategy, analytical methods, manufacturing processes, and regulatory expectations. Designed to enable seamless transition from North American clinical development to European Phase III and commercial manufacturing.
- Bora PharmaceuticalsflagshipStrategic alliance announced December 2025 to provide end-to-end oral solid dose development and manufacturing services. The collaboration combines Bora's global commercial infrastructure and scale-up capabilities with Corealis' formulation development and clinical-scale manufacturing expertise. Partners operate as a single integrated team with unified steering committee, shared quality framework, and joint delivery team. The alliance creates a seamless pathway from discovery through commercial launch for biotech and pharmaceutical companies.
- Prendio-BioProcureminorStrategic integration with Prendio procurement platform. Corealis' selective partner vetting ensures only organizations with proven track record of excellence are authorized to offer services through the platform, reflecting commitment to quality and scientific rigor.
- Science ExchangeminorCorealis integrated into the Science Exchange marketplace platform, enabling biotech companies to easily initiate proposal requests, align projects, manage communication, and ensure procurement compliance through a centralized online marketplace.
Scale indicators8 records
Recent moves7 records
Expansion highlights5 records
Corealis Pharma competitors and assessment
Company assessmentDirect peers
- Recipharm: European-headquartered CDMO with strong OSD capabilities across clinical and commercial supply. Directly comparable in service offering and biotech customer focus, though operates larger commercial-scale facilities across multiple geographies.
- Aenova: European CDMO specializing in solid dosage forms including tablets, capsules, and complex formulations. Closely comparable to Corealis in OSD specialization and biotech-to-pharma customer mix.
- Metrics Contract Services: US-based CDMO focused on OSD formulation, analytical services, and GMP clinical manufacturing for Phase I/II. Closely comparable niche specialist in early-phase OSD CDMO services.
- Rottendorf Pharma: European CDMO specializing in OSD development and commercial manufacturing. Corealis' strategic alliance partner and directly comparable specialist in OSD CDMO services with European market focus.
- Cambrex: CDMO providing API and drug product development/manufacturing including OSD capabilities. Comparable mid-sized CDMO with similar biotech-to-pharma customer base, though with stronger API offering than Corealis.
- Bora Pharmaceuticals: Taiwan-headquartered CDMO with OSD commercial manufacturing scale. Corealis' strategic alliance partner and direct peer in OSD services, though Bora's strength is in commercial-scale rather than early clinical manufacturing.
Broad incumbents
- Patheon (Thermo Fisher Scientific): Global CDMO within Thermo Fisher providing drug substance and drug product development, including OSD clinical manufacturing and commercial supply. Comparable in service scope but vastly larger and part of a broader life sciences platform.
- Almac Group: Global CDMO offering drug development, manufacturing, and clinical trial material services including OSD. Comparable service scope with broader clinical packaging and commercial manufacturing footprint.
- Lonza: Swiss-headquartered global CDMO with both small molecule and biologics capabilities. Overlaps with Corealis on OSD clinical manufacturing but operates at global scale with much broader modality coverage.
- Catalent: One of the largest global CDMOs offering OSD formulation, clinical and commercial manufacturing, and packaging. Direct overlap with Corealis on Phase I/II OSD services, but Catalent operates at significantly larger scale across multiple sites and modalities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Corealis Pharma social profiles
Digital presenceCorealis Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Corealis Pharma leadership team
Management profileNumber of profiles
Profiles8 records
Corealis Pharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Corealis Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Corealis Pharma
What does Corealis Pharma do?
Corealis Pharma is a Contract Development and Manufacturing Organization (CDMO) that provides formulation development and clinical supplies manufacturing of solid oral dosage forms for biotech and pharmaceutical companies. Its services span OSD pre-formulation (API characterization), formulation development, analytical services, Phase I/II GMP manufacturing of tablets and capsules, and clinical packaging/labeling with global distribution. Typical timelines run 4–6 months from project kickoff to clinical trial supply.
Is Corealis Pharma a public or private company?
Corealis Pharma is a private company. It is classified as private equity controlled and is currently operating.
When was Corealis Pharma founded?
Corealis Pharma was founded in 2005. It employs 11 to 50 people.
Where is Corealis Pharma based?
Corealis Pharma is headquartered in Laval, Canada, in the North America region.
How does Corealis Pharma make money?
Two revenue lines are on record. CDMO Contract Services are the primary driver. The others are clinical Supply Manufacturing.
Who are Corealis Pharma's main competitors?
Direct peers on record are Recipharm, Aenova, Metrics Contract Services, Rottendorf Pharma, Cambrex and Bora Pharmaceuticals. Broad incumbents are Patheon (Thermo Fisher Scientific), Almac Group, Lonza and Catalent.
Does Corealis Pharma have an API?
No public API is recorded for Corealis Pharma.
What industry is Corealis Pharma in?
Corealis Pharma's product category is Pharmaceutical CDMO Services (Oral Solid Dosage). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.